Arizona State, Mayo Clinic Researchers Identify Potential New Biomarkers for Diagnosing Crohn’s

Arizona State, Mayo Clinic Researchers Identify Potential New Biomarkers for Diagnosing Crohn’s
Researchers have identified novel biomarkers for diagnosing Crohn’s disease in a collaborative study between Arizona State University's Biodesign Institute and the Mayo Clinic. They also built a novel blood test that distinguishes patients from healthy individuals. Their study, "Identification of antibody against SNRPB, small nuclear ribonucleoprotein-associated proteins B and B', as an autoantibody marker in Crohn's disease using an immunoproteomics approach," appeared in the Journal of Crohn's and Colitis. Crohn’s disease is caused by inflammation in the digestive tract, and diagnosing it can be quite expensive and invasive. So scientists were eager to discover valuable molecules, or biomarkers, found only in Crohn's patients and that could be detected with a simple blood test. “To truly alter the natural history of Crohn’s disease and help people, we needed to develop a new test for early, accurate diagnosis, as well as administrating appro
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *